Psyomics

Cambridge, UK · ≈28 employees · psyomics.com

Psyomics is a precision mental health technology company based in Cambridge, United Kingdom, founded in 2015 as a spin-out from Cambridge University. Led by CEO Dr. Melinda Rees, the company focuses on enhancing mental health care through its AI-informed digital platform, Censeo. This platform streamlines the intake, triage, assessment, and diagnosis of over 15 mental and behavioral health conditions by capturing structured patient-reported data before clinical contact. The Censeo platform combines digital questionnaires with biological insights to support clinicians in assessing symptom profiles and needs. Psyomics also develops a dry blood spot test aimed at aiding the diagnosis of Bipolar Disorder, expected to launch in 2026. The company primarily serves healthcare providers, including the NHS, private mental health providers, and international partners, and is expanding its services to support children and young people by 2025. Psyomics aims to improve administrative efficiency and reduce clinical variation in mental health care, helping patients receive timely support.

Mental Health Care

Also: mental health · digital health · healthtech · system efficiency · bipolar disorder differentiation · digital mental health assessment · offices of all other health practitioners · co-morbidity detection · healthcare provider tools · machine learning algorithms · biomarker-based diagnostics · healthcare

Funding0

Every round, secondary, debt facility or acquisition involving Psyomics that Lounge tracks, newest first.

No rounds recorded yet.

Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.

See plans →Log in

Psyomics

Funding0

Key numbers

Also on Lounge

Similar companies